Abiraterone acetate (BioDeep_00000802425)
代谢物信息卡片
Abiraterone acetate
化学式: C26H33NO2 (391.25111580000004)
中文名称: 乙酸阿比特龙酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
InChI: InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
描述信息
A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo to abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors
C471 - Enzyme Inhibitor > C147923 - CYP17A1 Inhibitor
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:68639
- KEGGdrug: D09701
- PubChem: 9821849
- ChEMBL: CHEMBL271227
- MeSH: Abiraterone Acetate
- CAS: 154229-18-2
- MetaboLights: MTBLC68639
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Roshan Katekar, Sumati Sen, Mohammed Riyazuddin, Athar Husain, Richa Garg, Saurabh Verma, Kalyan Mitra, Jiaur R Gayen. Augmented experimental design for bioavailability enhancement: a robust formulation of abiraterone acetate.
Journal of liposome research.
2023 Mar; 33(1):65-76. doi:
10.1080/08982104.2022.2069811. [PMID: 35521749] - Jakub Petřík, Ondřej Rychecký, Tereza Krejčí, Lucia Becherová, Dan Trunov, Maximilián Prachár, Ondřej Navrátil, Pavel Žvátora, Lukáš Krejčík, Ondřej Dammer, Josef Beránek, Petr Kozlík, Tomáš Křížek, Miroslav Šoóš, Jakub Heřt, Samuele Bissola, Simone Berto, František Štěpánek. Pharmaceutical Product Characterization and Manufacturability of Surfactant-Enriched Oil Marbles with Abiraterone Acetate.
AAPS PharmSciTech.
2022 Oct; 23(7):274. doi:
10.1208/s12249-022-02430-6. [PMID: 36207549] - Klara K Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Kistorp, Rasmus Bisbjerg, Jens Faber, Tobias W Klausen, Ganesh Palapattu, Peter B Østergren. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
European journal of cancer (Oxford, England : 1990).
2022 08; 171(?):75-84. doi:
10.1016/j.ejca.2022.04.034. [PMID: 35709600] - A Küçükarda, A Gökyer, I Gökmen, E Özcan, M B Hacıoğlu, B Erdoğan, S Uzunoğlu, I Çiçin. Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
Actas urologicas espanolas.
2022 06; 46(5):301-309. doi:
10.1016/j.acuroe.2021.12.005. [PMID: 35256324] - Atish D Choudhury, Celestia S Higano, Johann S de Bono, Natalie Cook, Dana E Rathkopf, Kari B Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I Heath, Richard D Baird, Javier García-Carbacho, Miguel Quintela-Fandino, Simon T Barry, Elza C de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I Shapiro, Lillian L Siu, Aaron R Hansen. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 06; 28(11):2257-2269. doi:
10.1158/1078-0432.ccr-21-3087. [PMID: 35247924] - Ruba Almasri, Hayley B Schultz, Amalie Møller, Kristen E Bremmell, Alfonso Garcia-Bennett, Paul Joyce, Clive A Prestidge. Role of Silica Intrawall Microporosity on Abiraterone Acetate Solubilization and In Vivo Oral Absorption.
Molecular pharmaceutics.
2022 04; 19(4):1091-1103. doi:
10.1021/acs.molpharmaceut.1c00781. [PMID: 35238208] - Yu-Chao Ni, Jin-Ge Zhao, Meng-Ni Zhang, Yi-Jun Zhang, Zhen-Yu Yang, Ni Chen, Jun-Ru Chen, Peng-Fei Shen, Guang-Xi Sun, Xing-Ming Zhang, Yong-Hong Li, Hao Zeng. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
Asian journal of andrology.
2022 Mar; 24(2):154-160. doi:
10.4103/aja202143. [PMID: 34380864] - Kristina Snipaitiene, Arnas Bakavicius, Juozas R Lazutka, Albertas Ulys, Feliksas Jankevicius, Sonata Jarmalaite. Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
The Prostate.
2022 03; 82(4):475-482. doi:
10.1002/pros.24293. [PMID: 34970742] - ZhenHua Zhong, YuPing Chen, HongYing Xia, ZhenZhen Chen, QiZhen Cheng. Development and Validation of a Sensitive GC-MS/MS Method for the Determination of Five Potential Genotoxic Impurities in Abiraterone Acetate.
Journal of chromatographic science.
2022 Feb; 60(2):105-110. doi:
10.1093/chromsci/bmab052. [PMID: 34059885] - Fatih Genc, Ugur Simal Atabey, Riza Serttas, Suat Erdogan. Abiraterone Acetate, in Combination with Apigenin, Attenuates the Survival of Human Castration-Sensitive Prostate Cancer Cells.
Anti-cancer agents in medicinal chemistry.
2022; 22(18):3148-3156. doi:
10.2174/1871520622666220426095257. [PMID: 35473536] - Laura D Locati, Stefano Cavalieri, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Giuseppina Calareso, Luigi Mariani, Pasquale Quattrone, Salvatore Alfieri, Paolo Bossi, Francesca Platini, Iolanda Capone, Lisa Licitra. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021 12; 39(36):4061-4068. doi:
10.1200/jco.21.00468. [PMID: 34597119] - Yoshiyuki Sakai, Tatsuki Fukami, Mai Nagaoka, Keiya Hirosawa, Hiroyuki Ichida, Rei Sato, Kohei Suzuki, Masataka Nakano, Miki Nakajima. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.
Life sciences.
2021 Nov; 284(?):119896. doi:
10.1016/j.lfs.2021.119896. [PMID: 34450168] - Miguel E Jimenez Romero, Maria Camacho Gallego, Jose C Navarro Serrato, Miguel A Sanchez Hurtado, Jose D Santotoribio. Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
Anticancer research.
2021 Aug; 41(8):3955-3968. doi:
10.21873/anticanres.15192. [PMID: 34281859] - H Zhou, P Xu, Y Sun. Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs.
Die Pharmazie.
2021 07; 76(7):308-312. doi:
10.1691/ph.2021.0171. [PMID: 34256892] - A Jayaram, A Wingate, D Wetterskog, G Wheeler, C N Sternberg, R Jones, A Berruti, F Lefresne, M Lahaye, S Thomas, M Gormley, F Meacham, K Garg, L P Lim, A S Merseburger, B Tombal, D Ricci, G Attard. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021 06; 32(6):726-735. doi:
10.1016/j.annonc.2021.03.196. [PMID: 33794293] - Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, Francisco Gomez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka, Dominique Spaëth, Susan Feyerabend, Vsevolod Matveev, Florence Lefresne, Martin Lukac, Robert Wapenaar, Luis Costa, Simon Chowdhury. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Targeted oncology.
2021 05; 16(3):357-367. doi:
10.1007/s11523-021-00807-4. [PMID: 33826036] - F Rozet, P Mongiat-Artus, G Ploussard, M Rouprêt, P Cacoub, G Fournier, R Mathieu. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
2021 04; 31(5):243-244. doi:
10.1016/j.purol.2020.12.002. [PMID: 33468416] - Renske M T Ten Ham, Merel van Nuland, Rick A Vreman, Laurens G de Graaf, Hilde Rosing, André M Bergman, Alwin D R Huitema, Jos H Beijnen, Anke M Hövels. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
2021 01; 24(1):121-128. doi:
10.1016/j.jval.2020.04.1838. [PMID: 33431146] - Ismail Ould-Nana, Marine Cillis, Marco Gizzi, Valentine Gillion, Philippe Hantson, Ludovic Gérard. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Jan; 27(1):216-219. doi:
10.1177/1078155220923001. [PMID: 32397905] - Hitomi Yasukawa, Yoshinori Ikehata, Yasumasa Tsuboi, Naotaka Nishiyama, Akihiko Watanabe, Yasuyoshi Fujiuchi, Hiroshi Kitamura. [Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer].
Hinyokika kiyo. Acta urologica Japonica.
2020 Dec; 66(12):427-432. doi:
10.14989/actauroljap_66_12_427. [PMID: 33435652] - Meijun Du, Yijun Tian, Winston Tan, Liewei Wang, Liguo Wang, Deepak Kilari, Chiang-Ching Huang, Liang Wang, Manish Kohli. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
Prostate cancer and prostatic diseases.
2020 12; 23(4):705-713. doi:
10.1038/s41391-020-0224-4. [PMID: 32203070] - Brendan A Daisley, Ryan M Chanyi, Kamilah Abdur-Rashid, Kait F Al, Shaeley Gibbons, John A Chmiel, Hannah Wilcox, Gregor Reid, Amanda Anderson, Malcolm Dewar, Shiva M Nair, Joseph Chin, Jeremy P Burton. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients.
Nature communications.
2020 09; 11(1):4822. doi:
10.1038/s41467-020-18649-5. [PMID: 32973149] - Hayley B Schultz, Anthony D Wignall, Nicky Thomas, Clive A Prestidge. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
International journal of pharmaceutics.
2020 May; 582(?):119264. doi:
10.1016/j.ijpharm.2020.119264. [PMID: 32278053] - Stefanie L Groenland, Merel van Nuland, Andries M Bergman, Jeantine M de Feijter, Vincent O Dezentje, Hilde Rosing, Jos H Beijnen, Alwin D R Huitema, Neeltje Steeghs. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.
European journal of cancer (Oxford, England : 1990).
2020 05; 130(?):32-38. doi:
10.1016/j.ejca.2020.02.012. [PMID: 32172196] - Connor Wright, Patrick O'Day, Mohammed Alyamani, Nima Sharifi, Richard J Auchus. Abiraterone acetate treatment lowers 11-oxygenated androgens.
European journal of endocrinology.
2020 Apr; 182(4):413-421. doi:
10.1530/eje-19-0905. [PMID: 32045360] - Hayley B Schultz, Paul Joyce, Nicky Thomas, Clive A Prestidge. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
Pharmaceutical research.
2020 Mar; 37(4):77. doi:
10.1007/s11095-020-02795-y. [PMID: 32236761] - Eleni Efstathiou, Mark Titus, Sijin Wen, Patricia Troncoso, Anh Hoang, Paul Corn, Ina Prokhorova, John Araujo, Carl Dmuchowski, Amal Melhem-Bertrandt, Shiva Patil, Christopher J Logothetis. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
European urology oncology.
2020 02; 3(1):119-127. doi:
10.1016/j.euo.2019.01.008. [PMID: 31412017] - Merel van Nuland, Julie M Janssen, Bart van Hoek, Hilde Rosing, Jos H Beijnen, André M Bergman. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.
Clinical genitourinary cancer.
2019 10; 17(5):e893-e896. doi:
10.1016/j.clgc.2019.05.026. [PMID: 31248829] - Noriya Yamaguchi, Shuichi Morizane, Tetsuya Yumioka, Hideto Iwamoto, Katsuya Hikita, Takehiro Sejima, Masashi Honda, Atsushi Takenaka. Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
Anticancer research.
2019 Jul; 39(7):3879-3885. doi:
10.21873/anticanres.13538. [PMID: 31262916] - Malmaruha Arasaratnam, Megan Crumbaker, Atul Bhatnagar, Matthew J McKay, Mark P Molloy, Howard Gurney. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Cancer chemotherapy and pharmacology.
2019 07; 84(1):139-146. doi:
10.1007/s00280-019-03862-x. [PMID: 31081533] - Merel van Nuland, Nikkie Venekamp, Willemijn M E Wouters, Huub H van Rossum, Hilde Rosing, Jos H Beijnen. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
Journal of pharmaceutical and biomedical analysis.
2019 Jun; 170(?):161-168. doi:
10.1016/j.jpba.2019.03.043. [PMID: 30925273] - Liancheng Fan, Yan Yang, Chenfei Chi, Xiaowei Ma, Rui Wang, Yiming Gong, Hongying Zheng, Jiahua Pan, Yinjie Zhu, Baijun Dong, Wei Xue. Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
The Prostate.
2019 05; 79(6):567-573. doi:
10.1002/pros.23762. [PMID: 30614033] - Neil R Parikh, Claudia Huiza, Jill S Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P Lee, Warren S Inouye, Mark L Jordan, Homayoon Sanati, Lida Jafari, Carol J Bennett, Greg E Gin, Amar U Kishan, Robert E Reiter, Michael Lewis, Ahmad Sadeghi, William J Aronson, Isla P Garraway, Matthew B Rettig, Nicholas G Nickols. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
BMC cancer.
2019 Apr; 19(1):291. doi:
10.1186/s12885-019-5496-5. [PMID: 30935383] - Mohammed Bouhajib, Zia Tayab. Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.
Clinical drug investigation.
2019 Mar; 39(3):309-317. doi:
10.1007/s40261-019-00752-1. [PMID: 30671920] - Chunhua Wang, Chaoying Hu, Dan Gao, Zirun Zhao, Xiaoping Chen, Xiao Hu, Shili Gong, Lin Li, Lan Zhang. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.
Cancer chemotherapy and pharmacology.
2019 03; 83(3):509-517. doi:
10.1007/s00280-018-3754-x. [PMID: 30535959] - Giuseppe Di Lorenzo, Guru Sonpavde, Gregory Pond, Giuseppe Lucarelli, Sabrina Rossetti, Gaetano Facchini, Sarah Scagliarini, Giacomo Cartenì, Piera Federico, Bruno Daniele, Franco Morelli, Teresa Bellelli, Matteo Ferro, Sabino De Placido, Carlo Buonerba. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
European urology focus.
2018 12; 4(6):874-879. doi:
10.1016/j.euf.2017.03.015. [PMID: 28753882] - Cuiyun Li, Yanhua Ding, Deming Yang, Meng Wang, Yue Hu, Hong Zhang, Xiaoxue Zhu, Guiling Chen, Xiaojiiao Li, Min Wu, Jingrui Liu, Hong Chen, Chengjiao Liu, Zhenwei Shen, Bin Liu. Evaluation of reference-scaled average bioequivalence of two oral formulations of abiraterone acetate in healthy Chinese subjects
.
International journal of clinical pharmacology and therapeutics.
2018 Nov; 56(11):562-570. doi:
10.5414/cp203295. [PMID: 30220293] - Kotaro Suzuki, Mariko Sakamoto, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa. Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer.
Anticancer research.
2018 Oct; 38(10):5929-5935. doi:
10.21873/anticanres.12938. [PMID: 30275221] - Benoit Blanchet, Edith Carton, Mohammad Alyamani, Lisa Golmard, Olivier Huillard, Audrey Thomas-Scheomann, Michel Vidal, François Goldwasser, Nima Sharifi, Jérôme Alexandre. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.
Pharmacological research.
2018 10; 136(?):56-61. doi:
10.1016/j.phrs.2018.08.016. [PMID: 30142421] - Juozas Gordevičius, Algimantas Kriščiūnas, Daniel E Groot, Steven M Yip, Miki Susic, Andrew Kwan, Rafal Kustra, Anthony M Joshua, Kim N Chi, Art Petronis, Gabriel Oh. Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018 07; 24(14):3317-3324. doi:
10.1158/1078-0432.ccr-18-0101. [PMID: 29615462] - Yun-Jie Yang, Guo-Wen Lin, Gao-Xiang Li, Bo Dai, Ding-Wei Ye, Jun-Long Wu, Hu-Yang Xie, Yao Zhu. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.
Asian journal of andrology.
2018 Mar; 20(2):184-188. doi:
10.4103/aja.aja_39_17. [PMID: 29111539] - L Wang, S M Dehm, D W Hillman, H Sicotte, W Tan, M Gormley, V Bhargava, R Jimenez, F Xie, P Yin, S Qin, F Quevedo, B A Costello, H C Pitot, T Ho, A H Bryce, Z Ye, Y Li, P Eiken, P T Vedell, P Barman, B P McMenomy, T D Atwell, R E Carlson, M Ellingson, B W Eckloff, R Qin, F Ou, S N Hart, H Huang, J Jen, E D Wieben, K R Kalari, R M Weinshilboum, L Wang, M Kohli. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018 02; 29(2):352-360. doi:
10.1093/annonc/mdx689. [PMID: 29069303] - Cy A Stein, Richard Levin, Robert Given, Celestia S Higano, Paul Nemeth, Bill Bosch, Jillian Chapas-Reed, Robert Dreicer. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Urologic oncology.
2018 02; 36(2):81.e9-81.e16. doi:
10.1016/j.urolonc.2017.10.018. [PMID: 29150328] - Luca Cindolo, Clara Natoli, Cosimo De Nunzio, Michele De Tursi, Maurizio Valeriani, Silvana Giacinti, Salvatore Micali, Mino Rizzo, Giampaolo Bianchi, Eugenio Martorana, Marcello Scarcia, Giuseppe Mario Ludovico, Pierluigi Bove, Anastasia Laudisi, Oscar Selvaggio, Giuseppe Carrieri, Maida Bada, Pietro Castellan, Stefano Boccasile, Pasquale Ditonno, Paolo Chiodini, Paolo Verze, Vincenzo Mirone, Luigi Schips. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter 'real life' study.
BMC cancer.
2017 Nov; 17(1):753. doi:
10.1186/s12885-017-3755-x. [PMID: 29126389] - Satoru Yumiba, Kazuhiko Komori, Toshichika Iwanishi, Youhei Koida, Masao Kobayashi, Yutaka Ono. [A Case of Fulminant Hepatitis after Administration of Abiraterone Acetate].
Hinyokika kiyo. Acta urologica Japonica.
2017 Nov; 63(11):479-482. doi:
10.14989/actauroljap_63_11_479. [PMID: 29232800] - Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susane Krege, Jürgen Gschwend, Heidrun Rexer, Michael Stöckle. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Trials.
2017 Oct; 18(1):457. doi:
10.1186/s13063-017-2195-x. [PMID: 28978327] - Mohammad Alyamani, Zhenfei Li, Sunil K Upadhyay, David J Anderson, Richard J Auchus, Nima Sharifi. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column.
The Journal of steroid biochemistry and molecular biology.
2017 09; 172(?):231-239. doi:
10.1016/j.jsbmb.2016.04.002. [PMID: 27063554] - Elahe A Mostaghel, Eunpi Cho, Ailin Zhang, Mohammad Alyamani, Arja Kaipainen, Sean Green, Brett T Marck, Nima Sharifi, Jonathan L Wright, Roman Gulati, Lawrence D True, Massimo Loda, Alvin M Matsumoto, Daniel Tamae, Trevor N Penning, Steven P Balk, Phillip W Kantoff, Peter S Nelson, Mary-Ellen Taplin, R Bruce Montgomery. Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Aug; 23(16):4592-4601. doi:
10.1158/1078-0432.ccr-16-2245. [PMID: 28389510] - Tianzhu Zang, Mary-Ellen Taplin, Daniel Tamae, Wanling Xie, Clementina Mesaros, Zhenwei Zhang, Glenn Bubley, Bruce Montgomery, Steven P Balk, Elahe A Mostaghel, Ian A Blair, Trevor M Penning. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Endocrine-related cancer.
2017 08; 24(8):393-404. doi:
10.1530/erc-17-0107. [PMID: 28663228] - Liancheng Fan, Yanqing Wang, Chenfei Chi, Jiahua Pan, Shangguan Xun, Zhixiang Xin, Jianian Hu, Lixin Zhou, Baijun Dong, Wei Xue. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
BJU international.
2017 08; 120(2):226-232. doi:
10.1111/bju.13781. [PMID: 28107595] - Ronald Goldwater, Azra Hussaini, Bill Bosch, Paul Nemeth. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Clinical pharmacokinetics.
2017 07; 56(7):803-813. doi:
10.1007/s40262-017-0536-2. [PMID: 28425029] - Joannie Lefebvre, Ilya G Glezerman. Kidney Toxicities Associated With Novel Cancer Therapies.
Advances in chronic kidney disease.
2017 07; 24(4):233-240. doi:
10.1053/j.ackd.2017.05.006. [PMID: 28778363] - Christophe Massard, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean-Pascal Machiels, Alain Mita, Begoña Mellado, Sabine Turri, Joan Maier, Denes Csonka, Arunava Chakravartty, Karim Fizazi. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
European journal of cancer (Oxford, England : 1990).
2017 05; 76(?):36-44. doi:
10.1016/j.ejca.2017.01.024. [PMID: 28282611] - Baijun Dong, Liancheng Fan, Yanqing Wang, Chenfei Chi, Xiaowei Ma, Rui Wang, Wen Cai, Xiaoguang Shao, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Xiaonan Kang, Lixin Zhou, Wei Xue. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
The Prostate.
2017 May; 77(13):1373-1380. doi:
10.1002/pros.23397. [PMID: 28804908] - Marzia Del Re, Stefano Fogli, Lisa Derosa, Francesco Massari, Paul De Souza, Stefania Crucitta, Sergio Bracarda, Daniele Santini, Romano Danesi. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Cancer treatment reviews.
2017 Apr; 55(?):71-82. doi:
10.1016/j.ctrv.2017.03.001. [PMID: 28340451] - Geun Taek Lee, Christopher S Han, Young Suk Kwon, Rutveej Patel, Parth K Modi, Seok Joo Kwon, Izak Faiena, Neal Patel, Eric A Singer, Han-Jong Ahn, Wun-Jae Kim, Isaac Y Kim. Intracrine androgen biosynthesis in renal cell carcinoma.
British journal of cancer.
2017 Mar; 116(7):937-943. doi:
10.1038/bjc.2017.42. [PMID: 28253524] - Weimin Li, Joyce O'Shaughnessy, Daniel Hayes, Mario Campone, Igor Bondarenko, Irina Zbarskaya, Etienne Brain, Marina Stenina, Olga Ivanova, Marie-Pascale Graas, Patrick Neven, Deborah Ricci, Thomas Griffin, Thian Kheoh, Margaret Yu, Michael Gormley, Jason Martin, Michael Schaffer, Kathy Zelinsky, Peter De Porre, Stephen R D Johnston. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 Dec; 22(24):6002-6009. doi:
10.1158/1078-0432.ccr-15-2452. [PMID: 27267854] - Orazio Caffo, Nima Sharifi. Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?.
European urology.
2016 11; 70(5):898-899. doi:
10.1016/j.eururo.2016.06.013. [PMID: 27339836] - Sankar N Maity, Mark A Titus, Revekka Gyftaki, Guanglin Wu, Jing-Fang Lu, S Ramachandran, Elsa M Li-Ning-Tapia, Christopher J Logothetis, John C Araujo, Eleni Efstathiou. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Scientific reports.
2016 10; 6(?):35354. doi:
10.1038/srep35354. [PMID: 27748439] - Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W Smit, Caly Chien. In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity.
Drug metabolism and disposition: the biological fate of chemicals.
2016 10; 44(10):1682-91. doi:
10.1124/dmd.116.070672. [PMID: 27504016] - Sophie Geboers, Jef Stappaerts, Raf Mols, Jan Snoeys, Jan Tack, Pieter Annaert, Patrick Augustijns. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
Journal of pharmaceutical sciences.
2016 09; 105(9):2974-2981. doi:
10.1016/j.xphs.2016.03.008. [PMID: 27061460] - H-P Lipp, K Miller. [Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Der Urologe. Ausg. A.
2016 Jun; 55(6):766-71. doi:
10.1007/s00120-016-0049-x. [PMID: 26927871] - Zhenfei Li, Mohammad Alyamani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil K Upadhyay, Steven P Balk, Mary-Ellen Taplin, Richard J Auchus, Nima Sharifi. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Nature.
2016 05; 533(7604):547-51. doi:
10.1038/nature17954. [PMID: 27225130] - Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Markus Müller, Christian Bolenz, Christel Weiß, Elmar Heinrich. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
The Prostate.
2016 May; 76(7):613-9. doi:
10.1002/pros.23152. [PMID: 26779767] - Kim N Chi, Jennifer Spratlin, Christian Kollmannsberger, Scott North, Catherine Pankras, Martha Gonzalez, Apexa Bernard, Hans Stieltjes, Lixian Peng, James Jiao, Milin Acharya, Thian Kheoh, Thomas W Griffin, Margaret K Yu, Caly Chien, Nam Phuong Tran. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
Journal of clinical pharmacology.
2015 Dec; 55(12):1406-14. doi:
10.1002/jcph.564. [PMID: 26096139] - J T Stover, R A Moore, K Davis, M R Harrison, A J Armstrong. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
Prostate cancer and prostatic diseases.
2015 Jun; 18(2):161-6. doi:
10.1038/pcan.2015.7. [PMID: 25777155] - Apexa Bernard, Nicole Vaccaro, Milin Acharya, James Jiao, Johan Monbaliu, Ronald De Vries, Hans Stieltjes, Margaret Yu, Namphuong Tran, Caly Chien. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Clinical pharmacology in drug development.
2015 01; 4(1):63-73. doi:
10.1002/cpdd.132. [PMID: 27128004] - Mary-Ellen Taplin, Bruce Montgomery, Christopher J Logothetis, Glenn J Bubley, Jerome P Richie, Bruce L Dalkin, Martin G Sanda, John W Davis, Massimo Loda, Lawrence D True, Patricia Troncoso, Huihui Ye, Rosina T Lis, Brett T Marck, Alvin M Matsumoto, Steven P Balk, Elahe A Mostaghel, Trevor M Penning, Peter S Nelson, Wanling Xie, Zhenyang Jiang, Christopher M Haqq, Daniel Tamae, NamPhuong Tran, Weimin Peng, Thian Kheoh, Arturo Molina, Philip W Kantoff. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014 Nov; 32(33):3705-15. doi:
10.1200/jco.2013.53.4578. [PMID: 25311217] - Nobuaki Matsubara, Hiroji Uemura, Iwao Fukui, Masashi Niwakawa, Akito Yamaguchi, Koho Iizuka, Hideyuki Akaza. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Cancer science.
2014 Oct; 105(10):1313-20. doi:
10.1111/cas.12496. [PMID: 25117615] - W Kim, J O Jones, M Diamond, C Haqq, A Molina, E J Small, C J Ryan. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Prostate cancer and prostatic diseases.
2014 Sep; 17(3):292-9. doi:
10.1038/pcan.2014.27. [PMID: 25047002] - Richard J Auchus, Elizabeth O Buschur, Alice Y Chang, Gary D Hammer, Carole Ramm, David Madrigal, George Wang, Martha Gonzalez, Xu Steven Xu, Johan W Smit, James Jiao, Margaret K Yu. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.
The Journal of clinical endocrinology and metabolism.
2014 Aug; 99(8):2763-70. doi:
10.1210/jc.2014-1258. [PMID: 24780050] - Eva Gupta, Troy Guthrie, Winston Tan. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
BMC urology.
2014 Jul; 14(?):55. doi:
10.1186/1471-2490-14-55. [PMID: 25062956] - Thomas Marbury, Eric Lawitz, Robert Stonerock, Martha Gonzalez, James Jiao, Jim Breeding, Christopher Haqq, Peter Verboven, Hans Stieltjes, Margaret Yu, Arturo Molina, Milin Acharya, Caly Chien, NamPhuong Tran. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
Journal of clinical pharmacology.
2014 Jul; 54(7):732-41. doi:
10.1002/jcph.253. [PMID: 24374856] - C J Ryan, W Peng, T Kheoh, E Welkowsky, C M Haqq, D W Chandler, H I Scher, A Molina. Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Prostate cancer and prostatic diseases.
2014 Jun; 17(2):192-8. doi:
10.1038/pcan.2014.8. [PMID: 24637537] - Noboru Hara, Tsutomu Nishiyama. Androgen metabolic pathway involved in current and emerging treatment for men with castration resistant prostate cancer: intraprostatic androgens as therapeutic targets and endocrinological biomarkers.
Current drug targets.
2014; 15(13):1215-24. doi:
10.2174/1389450115666141024114736. [PMID: 25341420] - Aiqin Gong, Xiashi Zhu. β-Cyclodextrin sensitized spectrofluorimetry for the determination of abiraterone acetate and abiraterone.
Journal of fluorescence.
2013 Nov; 23(6):1279-86. doi:
10.1007/s10895-013-1261-3. [PMID: 23835913] - Charles J Ryan, Arturo Molina, Jinhui Li, Thian Kheoh, Eric J Small, Christopher M Haqq, Russell P Grant, Johann S de Bono, Howard I Scher. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013 Aug; 31(22):2791-8. doi:
10.1200/jco.2012.45.4595. [PMID: 23816964] - K N Chi, A Tolcher, P Lee, P J Rosen, C K Kollmannsberger, K P Papadopoulos, A Patnaik, A Molina, J Jiao, C Pankras, B Kaiser, A Bernard, N Tran, M Acharya. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology.
2013 Jan; 71(1):237-44. doi:
10.1007/s00280-012-2001-0. [PMID: 23064959] - A W Tolcher, K N Chi, N D Shore, R Pili, A Molina, M Acharya, T Kheoh, J J Jiao, M Gonzalez, A Trinh, C Pankras, N Tran. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology.
2012 Aug; 70(2):305-13. doi:
10.1007/s00280-012-1916-9. [PMID: 22752297] - Qingzhong Hu, Matthias Negri, Kerstin Jahn-Hoffmann, Yan Zhuang, Sureyya Olgen, Marc Bartels, Ursula Müller-Vieira, Thomas Lauterbach, Rolf W Hartmann. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Bioorganic & medicinal chemistry.
2008 Aug; 16(16):7715-27. doi:
10.1016/j.bmc.2008.07.011. [PMID: 18674917] - Carsten Jagusch, Matthias Negri, Ulrike E Hille, Qingzhong Hu, Marc Bartels, Kerstin Jahn-Hoffmann, Mariano A E Pinto-Bazurco Mendieta, Barbara Rodenwaldt, Ursula Müller-Vieira, Dirk Schmidt, Thomas Lauterbach, Maurizio Recanatini, Andrea Cavalli, Rolf W Hartmann. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.
Bioorganic & medicinal chemistry.
2008 Feb; 16(4):1992-2010. doi:
10.1016/j.bmc.2007.10.094. [PMID: 18061460] - Y Ideyama, M Kudoh, K Tanimoto, Y Susaki, T Nanya, T Nakahara, H Ishikawa, T Yoden, M Okada, T Fujikura, H Akaza, H Shikama. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
The Prostate.
1998 Sep; 37(1):10-8. doi:
10.1002/(sici)1097-0045(19980915)37:1<10::aid-pros3>3.0.co;2-c. [PMID: 9721064] - S E Barrie, G A Potter, P M Goddard, B P Haynes, M Dowsett, M Jarman. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
The Journal of steroid biochemistry and molecular biology.
1994 Sep; 50(5-6):267-73. doi:
10.1016/0960-0760(94)90131-7. [PMID: 7918112]